CooperCompanies Reports Q1 2024 Revenue Increase, Raises Fiscal Year Guidance for 2024

By Staff
Friday, March 1, 2024 12:24 AM SAN RAMON, Calif.—CooperCompanies (Nasdaq: COO)  yesterday announced the financial results for its fiscal first quarter ended Jan. 31, 2024. Overall, revenue increased 9 percent year-over-year to $931.6 million; CooperVision (CVI) revenue was up 7 percent to $621.5 million, and CooperSurgical (CSI) revenue was up 12 percent to $310.1 million. Al White, Cooper’s president and CEO, said, “We're off to an outstanding start this fiscal year. We delivered record quarterly revenues in Q1 with contact lenses growing solidly and fertility posting its 13th consecutive quarter of double-digit organic growth.

Alcon Reports Sales Growth in Q4 and Full-Year 2023

By Staff
Thursday, February 29, 2024 12:27 AM GENEVA—Alcon (SIX/NYSE:ALC), a global leader in eyecare, reported its financial results for the three and 12 months ending Dec. 31, 2023. For the fourth quarter of 2023, sales were $2.3 billion, an increase of 8 percent on a reported basis and 10 percent on a constant currency basis, as compared with the same quarter of the previous year. Sales for the full year 2023 were $9.4 billion, an increase of 8 percent on a reported basis and 10 percent on a constant currency basis, compared with the full year 2022.

Warby Parker Announces Fourth Quarter and Full Year 2023 Results

By Staff
Thursday, February 29, 2024 12:24 AM NEW YORK—Warby Parker Inc. (NYSE: WRBY), a direct-to-consumer lifestyle brand focused on vision for all, announced financial results for the fourth quarter and full year ending Dec. 31, 2023. Fourth quarter net revenue increased $15.4 million, or 10.5 percent, to $161.9 million compared with fourth quarter 2022.

National Vision Holdings, Inc. Reports Fourth Quarter and Fiscal 2023 Financial Results

By Staff
Wednesday, February 28, 2024 12:24 AM DULUTH, Ga.—National Vision Holdings, Inc. (NASDAQ: EYE), one of the largest optical retail companies in the U.S., reported its financial results for the fourth quarter and fiscal year ending Dec. 30, 2023, and provided its outlook for fiscal 2024. Net revenue increased 8.0 percent to $506.4 million compared with the fourth quarter of 2022, primarily due to an increase in adjusted comparable store sales growth and growth from new stores sales, partially offset by closed stores.

STAAR Surgical Reports Fourth Quarter and Fiscal Year 2023 Results

By Staff
Tuesday, February 27, 2024 12:18 AM LAKE FOREST, Calif.—STAAR Surgical Company, a leading developer, manufacturer and marketer of the EVO family of implantable collamer lenses for myopia, astigmatism and presbyopia, reported financial results for the fourth quarter and fiscal year ending Dec. 29, 2023.

Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results

By Staff
Friday, February 23, 2024 12:21 AM ALISO VIEJO, Calif.—Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced financial results for the fourth quarter and full year ending Dec. 31, 2023.

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 Guidance

By Staff
Thursday, February 22, 2024 12:24 AM VAUGHAN, Ontartio—Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, announced its fourth-quarter and full-year 2023 financial results. Total reported revenue was $1.173 billion for the fourth quarter of 2023, as compared to $996 million in the fourth quarter of 2022, an increase of $177 million, or 18 percent. Total reported revenue was $4.146 billion for the full year of 2023, as compared to $3.768 billion in the full year of 2022, an increase of $378 million, or 10 percent.

Vision Integrated Partners Completes Refinancing

By Staff
Thursday, February 22, 2024 12:18 AM ST. LOUIS—Vision Integrated Partners (VIP), a leader in providing ophthalmology practice and ambulatory surgery center management services, has successfully completed a recapitalization.

Western Optical Supply Changes Hands

By Staff
Friday, February 16, 2024 12:24 AM GREEN BAY, Wis.—Western Optical Supply Inc., a supplier and manufacturer of optical dispensing tools, was recently acquired from its founder, Joshua Freilich, by eyecare industry veteran, Joe Sabel, ABOC, and his wife Holly.

EssilorLuxottica Reports Record 2023 Fiscal Year Sales, Citing North America Acceleration in Q4

By Staff
Thursday, February 15, 2024 12:27 AM CHARENTON-LE-PONT, France—With senior executives pointing to fiscal 2023 sales rising 7 percent at constant exchange rates, "nice acceleration" in North America in Q4, its investment in new innovation technologies such as Varilux XR, Stellest and Ray-Ban Meta, and a strengthening of its luxury frame brand portfolio, EssilorLuxottica reported record revenues for the fiscal year ending Dec. 31, 2023. The company's board met on Feb. 14 to approve the consolidated financial statements for the period, statements audited by Statutory Auditors whose report is in the process of being issued.

Carl Zeiss Meditec Posts Slight Revenue Growth in Q1 of 2023/24

By Staff
Monday, February 12, 2024 12:18 AM JENA, Germany—Carl Zeiss Meditec AG generated revenue of €475.0 million in the first quarter of fiscal year 2023/24 (compared to the prior year: €470.3 million), corresponding to a growth of +1.0 percent (adjusted for currency effects: +3.3 percent).

Nicox Provides Fourth Quarter 2023 Financial Results

By Staff
Monday, January 29, 2024 12:15 AM SOPHIA ANTIPOLIS, France—Nicox SA, an international ophthalmology company, announced financial and business highlights for the fourth quarter of 2023 for Nicox SA and its subsidiaries.

Sight Sciences Announces Closing of Up to $65 Million Senior Secured Credit Facility With Hercules Capital

By Staff
Thursday, January 25, 2024 12:18 AM MENLO PARK, Calif.—Sight Sciences, Inc., an eyecare technology company, announced the closing of an up to $65 million senior secured credit facility with Hercules Capital, Inc., a leader in customized debt financing for companies in life sciences and technology-related markets.

Johnson & Johnson Reports Q4 and Full-Year 2023 Results and Reconfirms 2024 Guidance

By Staff
Wednesday, January 24, 2024 12:24 AM NEW BRUNSWICK, N.J.—Johnson & Johnson (NYSE: JNJ) announced results for the fourth-quarter and full year 2023. The 2023 fourth-quarter reported sales growth was 7.3 percent to $21.4 billion with operational growth of 7.2 percent and adjusted operational growth of 5.7 percent. Operational growth excluding the COVID-19 vaccine was 10.9 percent. Full-year 2023 sales growth was reported at 6.5 percent to $85.2 billion with operational growth of 7.4 percent and adjusted operational growth of 5.9 percent. Operational growth excluding the COVID-19 vaccine was 9.0 percent.

Glaukos Announces Preliminary Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance

By Staff
Thursday, January 11, 2024 12:18 AM ALISO VIEJO, Calif.—Glaukos Corporation, an ophthalmic medical tech and pharma company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced its preliminary, unaudited net sales for the fourth quarter and full year ended Dec. 31, 2023.